So Jung Imm

No ORCID on file · 5 papers in corpus · active 2021-2024

Study types

  • article 4
  • rct 1

Condition tags

  • endometriosis 5
  • dysmenorrhea 1
  • chronic_pelvic_pain 1
  • dyspareunia 1
rct 2024
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction ·doi:10.1093/humrep/dead263

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment wit…

article 2023
Bleeding Patterns With Relugolix Combination Therapy in Women With Endometriosis-Associated Pain [ID: 1345374]
·doi:10.1097/01.aog.0000929844.43483.20

INTRODUCTION: Relugolix combination therapy (Relugolix-CT: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) significantly improved endometriosis-associated pain versus placebo in the SPIRIT 1&2 studies. Efficacy was maintained…

article 2022
RELUGOLIX COMBINATION THERAPY IN NORTH AMERICAN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: SPIRIT 1 AND 2 TRIALS
·doi:10.1016/j.fertnstert.2022.08.633
article 2022
SUSTAINED IMPROVEMENT IN PHYSICAL FUNCTION AND QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN TREATED WITH RELUGOLIX COMBINATION THERAPY OVER 104 WEEKS: SPIRIT LONG-TERM EXTENSION STUDY
·doi:10.1016/j.fertnstert.2022.08.020
article 2021
RELUGOLIX COMBINATION THERAPY IMPROVES MULTIPLE DIMENSIONS OF QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM THE SPIRIT PROGRAM
·doi:10.1016/j.fertnstert.2021.07.146